Base de dados : LILACS
Pesquisa : D06.472.699.327.740.880 [Categoria DeCS]
Referências encontradas : 77 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 8 ir para página                    

  1 / 77 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Id: lil-748654
Autor: Santos, Kely; Pinto, Adriana Becker.
Título: Prevalência de alterações dos hormônios TSH e T4 livre empacientes atendidos em um laboratório de análises clínicas do município de Carazinho, RS / Prevalence of alterations in hormones TSH and free T4 in patientes attended in a laboratory clinical analyses in Carazinho, RS
Fonte: Rev. bras. anal. clin;45(1-4):45-48, 2013. tab, graf.
Idioma: pt.
Resumo: O TSH comanda todos os processos que envolvem a síntese e secreção da tireoide, além de manter seu metabolismo. O objetivo deste estudo foi verificar a prevalência de alterações nas dosagens séricas dos hormônios TSH e T4 livre em pacientes atendidos em um laboratório de análises clínicas do município de Carazinho - RS. O estudo foi composto por mil amostras de ambos os sexos, sendo realizado no período de junho 2007 a junho 2008. Nas mulheres, a faixa etária mais atingida pelo hipotireoidismo ficou entre 41 e 70 anos, representando 13,5%; nos homens, entre 51 e 70 anos, representando 12,6%. Com relação ao hipertireoidismo, não houve faixa etária prevalente nos sexos. No hipotireoidismo subclínico, obteve-se um percentual maior de alterações, tanto no sexo feminino quanto no masculino, representando, respectivamente, 25% e 36,4% dasalterações, quando comparado ao hipotireoidismo em sua apresentação clínica. A partir do estudo realizado, constatou-se que a principal alteração detectada nos hormônios da tireoide foi a forma subclínica, o que está de acordo com relatos encontrados na literaturamundial. Sabendo-se da importância destes hormônios em todo o metabolismo, torna-se fundamental o rastreamento para diagnóstico destas alterações a fim de evitar possíveisdanos decorrentes dessa patologia...
Descritores: Hipertireoidismo
Hipotireoidismo
Prevalência
Doenças da Glândula Tireoide
Glândula Tireoide
Hormônios Tireóideos
Tireotropina
Hormônio Liberador de Tireotropina
Tiroxina
Tri-Iodotironina
Limites: Seres Humanos
Masculino
Feminino
Gravidez
Recém-Nascido
Lactente
Pré-Escolar
Criança
Adolescente
Adulto Jovem
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  2 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-641907
Autor: Degrossi, O. J; Faure, E; Degrossi, Elina B; Damilano, S; Pinkas, Mirtha; Barmasch, Martha; García del Río, H; Alvarez, Liliana; Pena, Marta; Lopart, Iris; Mignogna, A.
Título: Estimulación iterativa (EI) de TSH endógena (TSH-En) mediante el uso de la hormona liberadora de tirotrofina (TRH) en pacientes portadores de carcinoma diferenciado de tiroides / Rapid iterative stimulation (IS) of endogenous tsh (En-TSH) utilizing thyrotropin releasing hormone (TRH) in patients with differentiated thyroid carcinoma (DTC)
Fonte: Rev. argent. endocrinol. metab;44(2):67-77, abr.-jun. 2007. graf, tab.
Idioma: es.
Resumo: En el CDT es indispensable elevar los valores de TSH para efectuar Tg y barrido (RCT) con 131I, debiéndose suspender la opoterapia (HT) durante 4/5 sem. con el consecuente hipotiroidismo (H) y los trastornos que conlleva. Nuestro objetivo fue incrementar en forma rápida TSH-E acortando el tiempo de abstinencia. Se efectuaron 43 estudios en 37 pacientes con CDT (G-1); de entre 19 y 78 años, 34 con forma papilar y 3 folicular de CDT, 12 de sexo masculino y 25 femenino Se consideraron 2 subgrupos, G-1A, 7 p. para ablación (A); G-1B, 36 p. para seguimiento (S) y/o tratamiento (T) entre 6 meses y 5 años poscirugía; 6 p. efectuaron dos estudios, 4 para A y S y 2 para 2 veces S. Como comparación se revisaron 41 estudios en 35 p (G-2) que efectuaron suspensión de opoterapia por 4/5 semanas, entre 18 y 81 años; 28 de sexo femenino y 7 masculino; 32 papilares y 3 foliculares; 18 para A (G-2 A) y 21 para S, primer control (G-2B); 4 p. efectuaron 2 estudios, A y S. G-1A: entre 8/10 días poscirugía se les administra TRH 200 mcg i.v los días 1, 3, 5 y 6. A los 30 min de la 3ra aplicación, determinación de TSH y RCT con 370 MBq de 99mT; a igual lapso en la 4ta aplicación determinación de TSH, Tg y antiTg y 5,55 o 7,4 GBq de 131I, para A; a los 8 días RCT con 131I. G-1B: se suspende T4 y reemplaza por T3 por 3 semanas. Se suspende T3; a las 24 horas se inicia el esquema indicado para G-1A . A la 4ta aplicación de TRH, se administra el 131I, 14,8 MBq y RCT a las 48 horas en S o la actividad terapéutica indicada para T. En ambos grupos se indicó dieta hipoyódica. Resultados: En G-1, los valores de TSH ascendieron a 26-360 UI/L; promedio 83 UI/L ± 54; G-1A : 137 ±109; G-1B 7, 62 ± 52 . Los RCT no mostraron diferencias con ambos trazadores. En G-1A todos los p presentaron remanentes tiroideos y Tg positivas. En G-1B, 21 p. mostraron RCT y Tg negativas; 7 áreas activas y Tg positivas y 8 p RCT negativos con valores elevados de Tg . En G-2, TSH, 23-170 UI/L ( 63 ± 3 UI/L) ; G-2 A: 71 ± 41 ; G-2B, 63 ± 42. Conclusiones: Estos hallazgos indican que a) la metodología propuesta es adecuada para acortar sensible-mente el tiempo de abstinencia de opoterapia y reducir la sintomatología del H que pasa desapercibida en la mayoría de los casos; b) los valores de TSH-En obtenidos son similares y aun superiores a los alcanzados por suspensión de opoterapia por lapsos prolongados; c) el empleo del RCT con 99mTc como indicador de tejido captante disminuye el uso terapéutico a ciegas de 131I al señalar casos de ausencia de concentración y permite, cuando sea necesario, obtener anticipadamente 131I para su empleo terapéutico.

In the follow up (F) of p with DTC it is necessary to obtain high figures of serum TSH for determination of serum Tg and 131I scan (WBS). For this object, he method, for a long time, was to withdrawal thyroid hormone therapy (generally l-T4) that produce hypothyroidism with the inconvenient for the p, dramatics in certain cases. Our objective was to increase TSH by IS to shortening time of L-T4 withdrawal for F, ablation (A) or treatment (T) with 131I. In 37 p. with DTC (G-1), aged 19-78 y., 34 with pap. DTC and 3 with foll. form, 25 females, 12 males, 43 studies were carried out; 6 p carried 2 studies. The group was divided in 2 sub-groups: G-1A,7 p derived for A; G-1 B 36 p. for F or T with 131I. Six p carried out 2 studies; 4 of them for A and for F and 2 realizes 2 times F. All p treated with l-T4 replaced this hormone for T3 during 3 weeks ,that was withdrawal the day before IS. In G-1A, between 8/10 days after surgery they begin IS. IS: At days 1, 3, 5 and 6, the p were injected i.v. with 200 mcg of TRH; at 30 minutes of the 3rd injec. blood TSH determination ; immediately 370 MBq of 99mT was administered and at 30 minutes a WBS was carried out. At 30 minutes of the 4th injec. blood figures of TSH, Tg and Tg-ab were determined; immediately the activity of 131I indicated for each group was given to the p; in G-1A, at 8 days and in G1-B, at 48 hours WBS were carried out. As a control group (G-2) 41 studies in 35 DTC p. that withdrawal l-T4 for 4/5 weeks, were studied, aged 18-81 years, 31 females and 4 males; 32 with pap. and 3 folli.c form; 18 for A (G-2A) and 23 for F (G-2B); 6 p carried out 2 studies. One for A and the second as the first control. In G-1, TSH values obtained were 26-360 UI/L ( 83 ± 54. In G-1A : 137 ± 109 and in G-1B 62 ± 52). The 2 tracers 131I and 99mTc-Tc, produce show similar figures. In G-1A all p present thyroid remnants and elevated Tg. In G-1B, 7 p showed positive WBS and Tg; 8 p present Tg positive and WBS negative and 21 WBS and Tg negative. In G-2, the TSH values obtained were 23-179 UI/L (63 ± 39 ); G-2A 71 ± 41 and G-2B 63 ± 42. These findings indicate that the methods is adequate to shortened the time of withdrawal of l-T4 and reduce the signs/symptoms of hypothyroidism to an acceptable status. Also allow us to considered the use of 99mTc as an indicator of existence of remnants, relapses or metastases and avoid blind use of therapeutic activities of 131I.
Descritores: Neoplasias da Glândula Tireoide/diagnóstico
Hormônio Liberador de Tireotropina/uso terapêutico
-Carcinoma/diagnóstico
Estimulação Química
Hormônio Liberador de Tireotropina/metabolismo
Limites: Seres Humanos
Masculino
Feminino
Adulto
Meia-Idade
Idoso
Tipo de Publ: Relatos de Casos
Estudo Comparativo
Responsável: AR1.2 - Instituto de Investigaciónes Epidemiológicas


  3 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-517507
Autor: Ugarte P., Francisca; Izquierdo C., Giannina; Zambrano O., Pedro; Pinto S., Viola; Cortés B., Alejandra; Fasce P., Gerardo.
Título: Función tiroidea en pacientes pediátricos con enfermedad renal crónica / Thyroid function in pediatric patients with chronic renal failure
Fonte: Rev. chil. pediatr;79(3):259-266, jun. 2008. tab.
Idioma: es.
Resumo: Objective: To characterize the thyroid function in mild (L), moderate (M), hemodialysis (HD), peritoneal dialysis (PD), chronic renal failure (CRE) and post kidney transplant (TX). Method: 46 children between 9.3 +/- 3.7 years-old with CRF (10 mild (L), 10 moderate (M), 10 peritoneodialysis (PD), 6 hemodialysis (HD), 10 transplants (TX)) were evaluated. Basal total T4 and free T3, TRH test (TSH at 0-30-60 min), creatinine, BUN, creatinine clearance and anthropometric parameters were measured. The statistics analysis included Anova Test to compare group results and correlation coefficients for studied variables. Results: Basal thyroid hormone levéis were normal in all groups and no differences between groups (except higher TSH in L (p < 0.01)) were found. TRH test response was prolonged on L, M, PD and HD and deficient in TX, except 3 TX patients who had normal TRH response, all using Tacrolimus, Micofenolate and Prednisone on altérnate day treatment versus the remaining TX who where on Cyclosporine or Azathioprine, Micofenolate and continuous corticoid régimen. Prolonged TRH response correlates with creatinine (p < 0.001) and creatinine clearance (p < 0,01). Conclusions: Basal thyroid hormones were normal in all groups. TRH test response was predominantly prolonged in L, M, PD and HD, suggesting adaptative phenomena at tertiary level, and correlates with renal function. TX patients had deficient TRH response, suggesting hypofisial dysfunction.

Objetivo: Caracterizar la función tiroidea y la respuesta a test de TRH (thyroid releasing hormone), en niños con enfermedad renal crónica (ERC) leve (L), moderada (M), peritoneodiálisis (PD), hemodiálisis (HD) y trasplantados renales (TX). Pacientes y Método: Se estudiaron 46 pacientes con ERC (10 L, 10 M, 10PD,6HDy 10TX),9,3 +/- 3,7 años. Se midió t4t,t41,t3t, t31,TBGbasalytest de TRH(TSHa 0,30y60min). Se evaluó función renal, antropometría y se consignó tratamiento inmunosupresor (IS) en el grupo TX. Se utilizó anova para comparar los resultados entre los grupos y coeficiente de correlación para las variables estudiadas. Resultados: Los valores basales de hormonas tiroideas fueron normales en todos los grupos, sólo TSH fue significativamente mayor en L aunque dentro del rango normal (p < 0,01). La respuesta al test de TRH fue predominantemente prolongada en L, M, PD y HD y deficiente en TX; los 3 pacientes TX con tacrolimus, micofenolato y prednisona en días alternos tuvieron respuesta normal a diferencia del resto TX que recibían prednisona continua, ciclosporina y micofenolato. La prolongación de respuesta a TRH se correlacionó con creatininemia, BUN y clearance de creatinina (p < 0,01). Conclusiones: Los niveles de hormonas tiroideas basales se encuentran normales en todos los grupos de ERC. La respuesta a TRH fue predominantemente prolongada en L, M, PD y HD, demostrando un fenómeno adaptativo a nivel terciario del eje hipotálamo-hipofisis-tiroides. Los TX presentan una respuesta mayoritoriamente deficiente a TRH, sugerente de disfunción hipofisiaria, la que podría estar relacionada con el tipo de tratamiento inmunosupresor y al uso de corticoides en días continuos.
Descritores: Glândula Tireoide/fisiopatologia
Hormônio Liberador de Tireotropina/farmacologia
Insuficiência Renal Crônica/fisiopatologia
-Antropometria
Relação Dose-Resposta a Droga
Glândula Tireoide
Hormônios Tireóideos/sangue
Insuficiência Renal Crônica/sangue
Transplante de Rim
Estudos Prospectivos
Diálise Renal
Testes de Função Tireóidea
Limites: Seres Humanos
Masculino
Feminino
Lactente
Pré-Escolar
Criança
Adolescente
Responsável: CL1.1 - Biblioteca Central


  4 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-495992
Autor: Jara Yorg, J A; Jara, M; Jara Ruiz, J M.
Título: Q12 cáncer diferenciado de tiroides (CDT): estimulación de la TSH endógena con múltiples dosis de TRH y su tratamiento con 131I: experiencia de 3 años / Differentiated thyroid carcinoma: endogenous TSH stimulation by multiple dosage of TRH and treatment with 131I
Fonte: Rev. med. nucl. Alasbimn j;10(41), jul. 2008. ilus, tab.
Idioma: es.
Resumo: La búsqueda un método alternativo a la rh-TSH para estimular el aumento de la TSH sérica previo al tratamiento con 131I en pacientes con CDT operados con reducción del tiempo del hipotiroidismo pre ablativo fue el propósito del trabajo que iniciamos en el año 2001 en el Paraguay utilizando múltiples dosis de TRH para estimular la TSH endógena de los pacientes para luego lograr la ablación del remanente tiroideo con 131I. Se conoce que la inyección de una dosis única de 200µU de TRH por vía EV logra el aumento de la TSH endógena en los pacientes con carcinoma diferenciado de tiroides logrando elevar la TSH entre 30 - 35 mUI/L al final de la primera hora , sin embargo, no se cuentan con datos estadísticos de los efectos de múltiples inyecciones de TRH aplicadas por vía EV o por vía IM en los pacientes operados de tiroides por CDT previamente a la ablación con 131I. Material y Método: Desde el 2001al 2007 doscientos pacientes operados por CDT fueron estudiados por este método en el Centro de Diagnostico y Tratamiento Nuclear (CEDIN), 120 correspondieron a cáncer papilar y 80 a cáncer folicular. Ciento ochenta no presentaron metástasis a distancia y 20 presentaron metástasis en cuello, tórax, pelvis y columna dorsal. Tiroidectomía total se realizó en 120 y lobectomía total e itsmectomía más hemilobectomía del lado contra lateral en 80. Todos fueron tratados con dosis ablativas (100 mCi (3.700 mBq) de 131I excepto aquellos con metástasis que recibieron 150 mCi (5.500 mBq) previa estimulación con TRH por vía EV en dos dosis diarias por dos días con previa suspensión de L-tiroxina por 25 días antes del tratamiento reemplazándola por triyodotironina 25 mcg/día por 15 días tras lo cual también fue suspendida 10 días antes de la estimulación con TRH y el tratamiento con 131I. Dos pacientes con metástasis recibieron otra dosis extra de 150 mCi (5.550 MBq) 6 meses después...

The search of an alternative method to the rh-TSH to stimulate endogenous rising of TSH previous to thyroid ablation with 131I in patients with CDT operated. The purpose of the work began in 2001 in Paraguay using multiple dose of TRH IV (200µU of TRH Threlea® Argentina) to stimulate the own TSH of patients previous to 131I ablation. It is known that the injection of an unique dose of 200µU of TRH IV achieves the increasing of the endogenous TSH in patients with differentiated thyroid carcinoma up to 30 - 35 mUI/L at the end of the first hour, however, there is not statistical data of the effects of multiple injections of TRH applied IV or IM in operated patients of DTC previous to the ablation with 131I. Since 2001-2007, two hundred patients operated for DTC were studied by this method, 120 were papillary cancer and 80 follicular cancer. One hundred eighty did not have distance metastasis and 20 presented metastasis in thorax, pelvis and dorsal spine. Total thyroidectomy was carried out in 120 and total lobectomy with itsmectomy plus hemilobectomy of the other lobe in 80. All were treated with ablative dose of 100 mCi (3.700 mBq) of 131I, except those with metastasis which receive 150 mCi (5.500 mBq) with the previous stimulation with TRH IV with two daily dose for three days with previous suspension of L-tiroxine for 25 days and replaced by triyodotiroxine 25 mcg/d for 15 days with suspension 10 days before the stimulation with TRH and treatment with 131I. Two patients with metastasis received another extra dose of 150 mCi (5.550 MBq) 6 months later. One presented uptake in thyroid bed one year after the ablation received a new ablative dose of 100 mCi (3.700 mBq) of 131I. All the patients were interned and isolated by 48 hours. Twenty feminine patients had later pregnancies in 1-3 years after their ablative dose with healthy products. TSH was measured during the stimulation with TRH in all patients...
Descritores: Adenocarcinoma Folicular
Carcinoma Papilar
Hormônio Liberador de Tireotropina/administração & dosagem
Hormônio Liberador de Tireotropina/farmacologia
Neoplasias da Glândula Tireoide/metabolismo
Neoplasias da Glândula Tireoide/radioterapia
Tireotropina
-Grupos Controle
Injeções Intravenosas
Metástase Neoplásica/radioterapia
Neoplasias da Glândula Tireoide/cirurgia
Neoplasias da Glândula Tireoide/patologia
Radioisótopos do Iodo/uso terapêutico
Fatores de Tempo
Tireoglobulina/análise
Tireoglobulina
Tireotropina/análise
Limites: Seres Humanos
Masculino
Feminino
Responsável: CL1.1 - Biblioteca Central


  5 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-486205
Autor: Arkader, Ronaldo; Takeuchi, Carlos Augusto.
Título: Shapiro syndrome with hypothalamic hypothyroidism / Síndrome de Shapiro assoociado a hipotireoidismo hipotalâmico
Fonte: Arq. neuropsiquiatr;66(2b):418-419, jun. 2008. ilus.
Idioma: en.
Descritores: Corpo Caloso/anormalidades
Hiperidrose/complicações
Doenças Hipotalâmicas/complicações
Hipotermia/complicações
Hipotireoidismo/complicações
-Ciproeptadina/uso terapêutico
Hiperidrose/tratamento farmacológico
Doenças Hipotalâmicas/tratamento farmacológico
Hipotermia/tratamento farmacológico
Hipotireoidismo/tratamento farmacológico
Imagem por Ressonância Magnética
Síndrome
Antagonistas da Serotonina/uso terapêutico
Hormônio Liberador de Tireotropina/deficiência
Tireotropina/deficiência
Tiroxina/uso terapêutico
Limites: Criança
Seres Humanos
Masculino
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  6 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-411537
Autor: Anon.
Título: Etiology and outcome of non-estrogen associated hyperthyroxinemia in euthyroid patients at the San Juan City Hospital
Fonte: Bol. Asoc. Méd. P. R;88(1/3):12-15, Jan.-Mar. 1996.
Idioma: en.
Resumo: INTRODUCTION: Hyperthyroxinemia does not always equate to hyperthyroidism. Laboratory tests should always be correlated with the clinical picture. A mismatch should make one doubt true hyperthyroidism. The purpose of our study was to assess the etiology of euthyroid hyperthyroxinemia not associated with estrogen use or pregnancy and to review the outcome of those erroneously treated. METHODS: The medical records of thirteen euthyroid patients with non estrogen associated hyperthyroxinemia were reviewed. They had a complete set of thyroid function tests including free T3 and free T4 by membrane dialysis, TRH stimulation test and thyroid hormone binding panel. RESULTS: Two diagnostic groups were identified: Hyperthyroxinemia secondary to binding abnormalities (7/13), better known as familial dysalbuminemic hyperthyroxinemia (FDH) and hyperthyroxinemia secondary to Thyroid Hormone Resistance (THR) (6/13). The FDH group had an elevated T4 and FTI, with normal T3RU, TSH, TRH stimulation test but an abnormal thyroid hormone binding panel which was used to confirm the diagnosis. The THR group had two laboratory presentations: Four patients presented with all the thyroid hormone tests elevated (T4, T3, T3RU, FTI) including a free T3 and free T4 by membrane dialysis with a normal TSH and TRH stimulation test and a normal T4 binding panel. This presentation is typical for a TRH patient with a nuclear receptor defect where all the precursos to the defect accumulate. Two patients with THR presented elevated T4 and free T4 but normal T3 and free T3, localizing the defect at the level of the active T4 transport mechanism across the cellular membrane. These two patients had a normal TSH, TRH stimulation test and T4 binding panel. Two patients were treated erroneously with radioactive iodine and became extremely hypothyroid in spite of normal TFTs. Very high dose of thyroid hormone replacement were required to restore euthyroidism. CONCLUSION: One must suspect these two entities in patients clinically euthyroid who have elevated T4 but non-suppressed TSH. A normal TSH and TRH test confirm euthyroidism. A thyroid hormone binding panel differentiates FDH from THR. Neither group require treatment. If treated erroneously and T4 drops to normal values, one must again induce hyperthyroxinemia to restore euthyroidism in these patients
Descritores: Hipertireoxinemia/etiologia
-Diagnóstico Diferencial
Hipertireoxinemia/diagnóstico
Hormônio Liberador de Tireotropina/sangue
Testes de Função Tireóidea
Tireotropina/sangue
Tiroxina/sangue
Limites: Seres Humanos
Masculino
Feminino
Gravidez
Adolescente
Adulto
Meia-Idade
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  7 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Monte, Osmar
Texto completo
Id: lil-409732
Autor: Monte, Osmar; Zyngier, Szulin; Kimura, Edna T; Bianco, Antonio C.
Título: Vias dopaminérgicas e somatostatinérgicas diminuem o TSH sérico em ratos portadores de carcinoma mamário walker-256 / Dopaminergic and somatostatinergic pathways decrease serum thyrotropin in rats bearing the 256-walker mammary carcinoma
Fonte: Arq. bras. endocrinol. metab;49(2):253-264, abr. 2005. tab, graf.
Idioma: pt.
Resumo: A funcão do eixo hipotálamo-hipófise-tireóide em animais portadores da "síndrome do T3 baixo", foi estudada em ratos implantados com o tumor de Walker-256. Ratos machos adultos foram injetados com 1 x 106 células tumorais viáveis, por via SC, e sacrificados após 10 dias. A intensidade da síndrome guardou relacão positiva com o tamanho do tumor desenvolvido. Houve diminuicão da atividade tireoideana documentada pela diminuicão da área nuclear das células foliculares, das concentracões plasmáticas do T4, da rTg e da captacão do 131I. Mesmo o implante SC de um pellet de TSH de liberacão lenta causou menor estimulacão tireoideana, avaliada após 2 e 24h nos ratos com tumor. A secrecão do rTSH avaliada através da administracão IV de TRH mostrou-se significativamente diminuída nestas condicões, indicando aumento do tônus inibidor hipotalâmico sobre a secrecão deste hormônio. A participacão de outros neuro-mediadores hipotalâmicos foi verificada através da administracão prévia de metoclopramida e/ou fisostigmina, com ou sem estímulo subseqüente pelo TRH. Nos animais tratados com metoclopramida, os valores do rTSH aumentaram significativamente, assim como a resposta ao estímulo de secrecão pelo TRH. A fisostigmina mostrou-se mais eficiente na mediacão da resposta de secrecão do rTSH, bem como na resposta ao estímulo de secrecão pelo TRH. A administracão concomitante dos dois fármacos, seguida do estímulo pelo TRH, normalizou a secrecão do rTSH. Conclui-se que, além das alteracões conhecidas do metabolismo das iodotironinas, a secrecão de TSH encontra-se diminuída nos animais portadores de tumor de Walker-256, sugerindo diminuicão global do tônus tireoideano.
Descritores: /metabolismo
CARCINOMA ADENOSINE KINASE, WALKER/metabolismo
Síndromes do Eutireóideo Doente/etiologia
Sistema Hipotálamo-Hipofisário/fisiologia
Neoplasias Mamárias Experimentais/metabolismo
Hormônios Tireóideos/sangue
Tireotropina/sangue
-Dopamina/farmacologia
Síndromes do Eutireóideo Doente/metabolismo
Sistema Hipotálamo-Hipofisário/efeitos dos fármacos
Metoclopramida/farmacologia
Fisostigmina/farmacologia
Hormônio Liberador de Tireotropina/sangue
Ratos Sprague-Dawley
Somatostatina/farmacologia
Glândula Tireoide/efeitos dos fármacos
Glândula Tireoide/metabolismo
Hormônios Tireóideos/metabolismo
Tireotropina
Limites: Ratos
Animais
Seres Humanos
Masculino
Responsável: BR1.1 - BIREME


  8 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-333642
Autor: Schally, Andrew V; Gual, Carlos.
Título: Antología de los primeros estudios clínicos con hormonas hipotalámicas: relato de una exitosa colaboración internacional / Anthology of the first clinical studies with hypothalamic hormones: a story of successful international cooperation
Fonte: Gac. méd. Méx;138(1):89-100, ebe.-feb. 2002.
Idioma: es.
Resumo: Our early pioneering clinical trials in Mexico with natural and synthetic thyrotropin-releasing hormone (TRH) and luteinizing hormone releasing hormone (LH-RH) also known as gonadotropin releasing hormone (Gn-RH), were reviewed. Highly purified TRH of porcine origin was shown to stimulate Thyrotropin (TSH) release in hypothyroid cretins. Subsequent tests with synthetic TRH also demonstrated significant increases in plasma TSH in normal men and women as well as in patients with primary hypothyroidism and other endocrine disorders. Even more extensive clinical studies were carried out with highly purified natural porcine LH-RH. Subjects with normal basal serum levels of gonadotropins, low levels (men and women pretreated with steroids) and high levels (e.g. post menopausal women) all responded to LH-RH with a release of LH and FSH. The results of these early studies with the natural LH-RH were confirmed by the use of synthetic LH-RH. These investigations made in Mexico with TRH and LH-RH preceded all other clinical studies by a wide margin. Subsequently various clinical investigations with LH-RH agonists and antagonists were also carried out. All these studies played a major role in introducing hypothalamic-releasing hormones into clinical medicine.
Descritores: Ensaios Clínicos como Assunto
Hormônio Liberador de Gonadotropina
Cooperação Internacional
Hormônio Liberador de Tireotropina
Limites: Seres Humanos
Responsável: BR1.1 - BIREME


  9 / 77 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-320640
Autor: Traina, Evelyn; Camacho-Lobato, Luciana; Borges, Darval Rosa.
Título: TRH-TSH test in patients with schistosomiasis chronic forms
Fonte: Rev. Inst. Med. Trop. Säo Paulo;38(3):227-228, May-Jun. 1996.
Idioma: en.
Descritores: Esquistossomose mansoni
Tireotropina
Hormônio Liberador de Tireotropina
-Doença Crônica
Tiroxina
Tri-Iodotironina
Limites: Adulto
Seres Humanos
Masculino
Meia-Idade
Responsável: BR1.1 - BIREME


  10 / 77 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Vaisman, Mario
Texto completo
Id: lil-316290
Autor: Novis, Mônica; Vaisman, Mario; Coelho, Hhenrique Sérgio Moraes.
Título: Teste da função tiroidiana na hepatite crônica viral / Thyroid function tests in viral chronic hepatitis
Fonte: Arq. gastroenterol;38(4):254-260, out.-dez. 2001. tab, graf.
Idioma: pt.
Resumo: One hundred and twenty five patients with virus B or C chronic active hepatitis and postnecrotic cirrhosis and different degrees of liver dysfunction were studied. AIM: 1) To determine a thyroid hormonal profile; 2) to evaluate the prognostic value of these tests in relation to the progression of the disease and mortality; 3) compare these findings with Child-Pugh classification. PATIENTS AND METHODS: The patients were divided in four groups: a) 31 with chronic active hepatitis; b) 41 with postnecrotic cirrhosis Child A; c) 35 with postnecrotic cirrhosis Child B and d) 18 with postnecrotic cirrhosis Child C. The protocol comprised serum measurements of albumin and bilirrubin, estimates of prothrombin time and clinical evaluation of ascites and encephalopathy, measurement of total serum triiodothyronine, thyroxine, thyroid-stimulating hormone, free thyroxine, reverse triiosothyronine, calculated rT3/T3 index (IrT3) and thyrotropin-releasing hormone test. RESULTS: Total serum triiodothyromnine showed the most significant difference among the groups, gradually lower as the disease became more advanced (CAH: 149.2 +/- 42.3 ng/dL; PNC-A: 137.4 +/- 37.2 ng/dL; PNC-B: 88.0 +/- 28.4 ng/dL and PNC-C: 41.8 +/- 21.9 ng/dL). Low levels of T4 (4.5 +/- 2.0 micrograms/dL) and FT4 (0.7 +/- 0.4 ng/dL) and elevated levels of thyroid-stimulating hormone (7.2 +/- 11.5 microIU/mL), reverse triiosothyronine (60.8 +/- 52.1 ng/dL) and calculated rT3/T3 index (2.2 +/- 2.6) were more frequent in patients with postnecrotic cirrhosis Child C. Thyrotropin-releasing hormone test was normal in the majority of the patients. CONCLUSION: The present study shows a positive relationship between the low serum levels of T3 and elevated serum levels of rT3 and IrT3/T3 with the degree of hepatic dysfunction according to the Child-Pugh classification
Descritores: Hepatopatias
Testes de Função Tireóidea
Glândula Tireoide
Hormônios Tireóideos
-Hepatite B Crônica
Hepatite C Crônica
Cirrose Hepática
Tireotropina
Hormônio Liberador de Tireotropina
Limites: Seres Humanos
Responsável: BR1.1 - BIREME



página 1 de 8 ir para página                    
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde